Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Half-year report · Q2

4886.TEDINET S100UNSK
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥32.4bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥62.8bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥31.6bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥3.3bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥3.1bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥3.3bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥6.5bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.1bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥3.3bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥5.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥2.6bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥7.5bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.6bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥4.1bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥88.3bnat 2024-09-30Cons.Assets
Total assets¥90.7bnat 2024-03-31Cons.Assets
Total assets¥91.9bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥24.1bnat 2024-09-30Cons.Liabilities
Total liabilities¥28.8bnat 2024-03-31Cons.Liabilities
Net assets / equity¥64.2bnat 2024-09-30Cons.Net assets
Net assets / equity¥61.9bnat 2024-03-31Cons.Net assets
Net assets / equity¥58.6bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥12.7bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥13.7bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥13.7bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥16.7bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥19.4bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥17.5bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.2bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥1.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥1.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥1.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥2.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥3.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥90.362024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥266.512023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥145.932023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio72.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio68.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.8%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-09-30¥151m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-09-30¥113m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-09-30¥38m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-09-30−¥4m
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥38m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥38m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥652m
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥3.6bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥3.6bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥177m
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥28.6bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥28.6bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.8bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥32.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥32.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥38m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥4.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥108m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥80m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥27m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥61m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥27m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥27m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥585m
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥44m
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥28.4bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥28.4bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥31.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥31.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥27m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥3.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 456
ItemContextValueUnit
Retained earningsPrior1YearInstant56372000000JPY
Retained earningsCurrentQuarterInstant58365000000JPY
Treasury stockPrior1YearInstant-3287000000JPY
Treasury stockCurrentQuarterInstant-3239000000JPY
Shareholders equityPrior1YearInstant56130000000JPY
Shareholders equityCurrentQuarterInstant58207000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant4790000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant4676000000JPY
Foreign currency translation adjustmentPrior1YearInstant424000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant755000000JPY
Remeasurements of defined benefit plansPrior1YearInstant584000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant552000000JPY
Valuation and translation adjustmentsPrior1YearInstant5799000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant5985000000JPY
Net assetsPrior1YearInstant61930000000JPY
Net assetsCurrentQuarterInstant64192000000JPY
Liabilities and net assetsPrior1YearInstant90745000000JPY
Liabilities and net assetsCurrentQuarterInstant88263000000JPY
Net salesPrior1YTDDuration31648000000JPY
Net salesCurrentYTDDuration32371000000JPY
Cost of salesPrior1YTDDuration16461000000JPY
Cost of salesCurrentYTDDuration16463000000JPY
Gross profitPrior1YTDDuration15186000000JPY
Gross profitCurrentYTDDuration15907000000JPY
Selling general and administrative expensesPrior1YTDDuration12130000000JPY
Selling general and administrative expensesCurrentYTDDuration12561000000JPY
Operating incomePrior1YTDDuration3055000000JPY
Operating incomeCurrentYTDDuration3345000000JPY
Interest income noiPrior1YTDDuration2000000JPY
Interest income noiCurrentYTDDuration1000000JPY
Dividends income noiPrior1YTDDuration187000000JPY
Dividends income noiCurrentYTDDuration148000000JPY
Other noiPrior1YTDDuration34000000JPY
Other noiCurrentYTDDuration55000000JPY
Non operating incomePrior1YTDDuration224000000JPY
Non operating incomeCurrentYTDDuration204000000JPY
Interest expenses noePrior1YTDDuration21000000JPY
Interest expenses noeCurrentYTDDuration22000000JPY
Loss on disposal of noncurrent assets noePrior1YTDDuration3000000JPY
Loss on disposal of noncurrent assets noeCurrentYTDDuration101000000JPY
Other noePrior1YTDDuration158000000JPY
Other noeCurrentYTDDuration113000000JPY
Non operating expensesPrior1YTDDuration183000000JPY
Non operating expensesCurrentYTDDuration238000000JPY
Ordinary incomePrior1YTDDuration3096000000JPY
Ordinary incomeCurrentYTDDuration3312000000JPY
Gain on sales of investment securities eiPrior1YTDDuration2314000000JPY
Gain on sales of investment securities eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration2314000000JPY
Extraordinary incomeCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass